No Data
No Data
Decoding 6 Analyst Evaluations For Viridian Therapeutics
Viridian Therapeutics Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $27 Price Target
H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $27
Analysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Solid Biosciences (SLDB)
Buy Rating for Viridian Therapeutics Backed by Strong Clinical Pipeline and Financial Health